文献速递心律失常心力衰竭与心肌病冠心病

结构性心脏病患者室性心动过速射频消融术后早期死亡率

Early Mortality After Catheter Ablation of Ventricular Tachycardia in Patients With Structural Heart Disease.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

本研究在12个国际中心纳入2061例结构性心脏病接受室性心动过速射频消融的患者,术后31天内早期死亡发生率为5%(95%CI 4%-6%),多因素分析显示低LVEF、慢性肾病、室速风暴及不可标测室速与早期死亡独立相关,术后室速复发亦增加死亡风险。

要点

  • 结构性心脏病患者VT射频消融术后31天内早期死亡率为5%(95%CI 4%-6%)。
  • LVEF每降低1%,早期死亡风险OR为1.12(95%CI 1.05-1.20;p<0.001)。
  • 室速风暴、慢性肾病、不可标测室速及术后室速复发与早期死亡风险升高相关。

核心结论

  • 在当代瘢痕相关室速接受射频消融的患者队列中,早期死亡发生于5%的病例。
  • 反映临床状态较差的临床和手术变量(低LVEF、慢性肾病、室速风暴、不可标测室速)及术后室速复发可能预测早期死亡。

研究设计与样本

  • 多中心研究,纳入12个国际中心的结构性心脏病接受室速射频消融的患者2061例,平均年龄62±13岁,LVEF 34±13%,53%为缺血性病因。
  • 评估术后31天内早期死亡与临床及手术变量的关联。

主要发现

  • 2061例患者中100例(5%;95%CI 4%-6%)发生早期死亡。
  • 54例(3%)在出院前死亡(中位术后9天;其中25%死于难治性室速),包括12例(0.6%)发生在重大手术相关并发症后。
  • 多因素分析中与早期死亡显著相关的因素:LVEF每降低1%(OR 1.12;95%CI 1.05-1.20;p<0.001)、慢性肾病(OR 2.73;95%CI 1.10-6.80;p=0.030)、以室速风暴起病(OR 3.61;95%CI 1.37-9.48;p=0.009)、存在不可标测室速(OR 5.69;95%CI 1.37-23.69;p=0.017)。
  • 室速复发与后续死亡风险升高相关(HR 7.19;95%CI 5.57-9.28;p<0.001),也与早期死亡风险升高相关(HR 11.45;95%CI 7.47-17.59;p<0.001)。

临床怎么用

  • 识别低LVEF、慢性肾病、室速风暴、不可标测室速等特征可能促使早期考虑血流动力学支持或其他照护,以帮助减轻后期潜在并发症。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients referred for radiofrequency catheter ablation (RFCA) of ventricular tachycardia (VT) in the setting of structural heart disease, early post-procedural mortality (EM) has not been previously investigated. OBJECTIVES: The purpose of this study was to evaluate EM after catheter ablation of scar-related VT. METHODS: Associations between clinical and procedural variables and EM (within 31 days of the procedure) were tested in patients with structural heart disease undergoing RFCA of VT at 12 international centers. RESULTS: Of 2,061 patients (mean age 62 ± 13 years; left ventricular ejection fraction [LVEF] 34 ± 13%; 53% ischemic etiology), EM occurred in 100 (5%; 95% confidence interval [CI]: 4% to 6%). A total of 54 (3%) patients died before hospital discharge (median 9 days after the procedure; 25% for refractory VT), including 12 (0.6%) after a major procedure-related complication. In multivariable analysis, the following factors were found to be significantly associated with EM: LVEF (odds ratio [OR] per percent decrease: 1.12; 95% CI: 1.05 to 1.20; p < 0.001), chronic kidney disease (OR: 2.73; 95% CI: 1.10 to 6.80; p = 0.030), presentation with VT storm (OR: 3.61; 95% CI: 1.37 to 9.48; p = 0.009), and presence of unmappable VTs (OR: 5.69; 95% CI: 1.37 to 23.69; p = 0.017). Recurrent VT was also associated with an increased risk of subsequent death (hazard ratio: 7.19; 95% CI: 5.57 to 9.28; p < 0.001) and EM (hazard ratio: 11.45; 95% CI: 7.47 to 17.59; p < 0.001). CONCLUSIONS: In a contemporary cohort of patients with scar-related VT undergoing RFCA, EM occurred in 5% of cases. Clinical and procedural variables indicating poorer clinical status (low LVEF, chronic kidney disease, VT storm, and unmappable VTs) and post-procedural VT recurrence may predict EM. Identification of such features may prompt early consideration for hemodynamic support or other care to help mitigate later potential complications.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Santangeli P, Frankel DS, Tung R, et al. Early Mortality After Catheter Ablation of Ventricular Tachycardia in Patients With Structural Heart Disease. J Am Coll Cardiol. 2017. PMID: 28449770. doi:10.1016/j.jacc.2017.02.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。